CIP
NVCR icon

Convergence Investment Partners’s NovoCure NVCR Stock Holding History

Convergence Investment Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,180
Closed -$204K – 267
2020
Q4 		$204K Buy
+1,180
New +$161K 0.1% 180

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Convergence Investment Partners's NVCR Position: Q1 2021 in Review

Convergence Investment Partners sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 1,180 shares — an estimated $204K sold.

Convergence Investment Partners first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $204K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Convergence Investment Partners reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Convergence Investment Partners sold 1,180 NovoCure shares in Q1 2021, an estimated $204K.
  • Convergence Investment Partners first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
  • Convergence Investment Partners's NovoCure position peaked at $204K in Q4 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Convergence Investment Partners's 13F filing for Q1 2021, filed 30 Apr 2021.